YBX1 and hepatocellular carcinoma: This interaction unveils a potential therapeutic avenue by combining IRGM inhibition with immune checkpoint inhibitors, highlighting YBX1’s pivotal role in the regulation of immune responses in hepatocellular carcinoma.